参考文献
(在框内滑动手指即可浏览)
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2] Al-Qurayshi Z, Nilubol N, Tufano RP, et al. Wolf in Sheep's Clothing: papillary thyroid microcarcinoma in the US[J]. J Am Coll Surg,2020,230(4):484-491.
[3] Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg,2010,34(1):28-35.
[4] Ito Y, Miyauchi A, Oda H, et al. Revisiting low-risk thyroid papillary microcarcinomas resected without observation: was immediate surgery necessary? [J].World J Surg,2016,40(3):523-528.
[5] Sugitani I, Ito Y, Takeuchi D, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma[J]. Thyroid,2021,31(2):183-192.
[6] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid,2016,26(1):1-133.
[7] 中国抗癌协会甲状腺癌专业委员会(CATO).甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J].中国肿瘤临床,2016,43(10):405-411.
[8] Yabuta T, Matsuse M, Hirokawa M, et al. TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance[J]. Thyroid, 2017,27(9):1206-1207.
[9] de Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid,2015,25(9):1013-1019.
[10] Kim KJ, Kim SG, Tan J, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma[J]. Eur J Cancer,2020,124:161-169.
[11] Fukuoka O, Sugitani I, Ebina A, et al. Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance[J]. World J Surg,2016,40(3):529-537.
[12] Sugitani I, Ito Y, Miyauchi A, et al. Active surveillance versus immediate surgery: questionnaire survey on the current treatment strategy for adult patients with low-risk papillary thyroid microcarcinoma in Japan[J]. Thyroid,2019,29(11):1563-1571.
[13] Oh HS, Ha J, Kim HI, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: A multi-center cohort study in Korea[J]. Thyroid,2018,28(12):1587-1594.
[14] Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance[J]. JAMA Otolaryngol Head Neck Surg, 2017,143(10):1015-1020.
[15] Rosario PW, Mourão GF, Calsolari MR. Active surveillance in adults with low-risk papillary thyroid microcarcinomas: A prospective study[J]. Horm Metab Res, 2019,51(11):703-708.
[16] Molinaro E, Campopiano MC, Pieruzzi L, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: Experience at a single Italian center[J]. J Clin Endocrinol Metab,2020,105(3):e172-e180.
[17] Cho SJ, Suh CH, Baek JH, et al. Active surveillance for small papillary thyroid cancer: A systematic review and meta-analysis[J]. Thyroid, 2019,29(10):1399-1408.
[18] Ding M, Tang X, Cui D, et al. Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma[J]. Clin Radiol,2019,74(9):712-717.
[19] Cho SJ, Baek SM, Lim HK, et al. Long-term follow-up results of ultrasound-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: more than 5-year follow-up for 84 tumors[J]. Thyroid,2020,30(12):1745-1751.
[20] 中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,中国医师协会介入医师分会肿瘤消融专业委员会,中国抗癌协会肿瘤介入专业委员会,中国抗癌协会肿瘤微创治疗专业委员会.甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版) [J].中国肿瘤,2018,27(10):768-773.
[21] Kim BY, Choi N, Kim SW, et al. Randomized trial of prophylactic ipsilateral central lymph node dissection in patients with clinically node negative papillary thyroid microcarcinoma[J]. Eur Arch Otorhinolaryngol,2020,277(2):569-576.
[22] Zhang Q, Wang Z, Meng X, et al. Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases[J]. Asian J Surg, 2019,42(4):571-576.
[23] 中国医师协会外科医师分会甲状腺外科医师委员会,中国研究型医院学会甲状腺疾病专业委员会,海峡两岸医药卫生交流协会海西甲状腺微创美容外科专家委员会,等.经胸前入路腔镜甲状腺手术专家共识(2017版)[J].中国实用外科杂志,2017,37(12):1369-1373.
[24] 中国医师协会外科医师分会甲状腺外科医师委员会,中国研究型医院学会甲状腺疾病专业委员会,海峡两岸医药卫生交流协会台海甲状腺微创美容外科专家委员会,等.经口腔前庭入路腔镜甲状腺手术专家共识(2018版)[J].中国实用外科杂志,2018,38(10):1104-1107.
[25] Wu GY, Fu JB, Lin FS, et al. Endoscopic central lymph node dissection via breast combined with oral approach for papillary thyroid carcinoma: A preliminary study[J]. World J Surg, 2017,41(9):2280-2282.
[26] 王娴,谌业荣,张国梁,等.超声诊断甲状腺微小乳头状癌腺外侵犯的影响因素分析[J].临床超声医学杂志,2020,22(6):407-410.
[27] 陈蕾,陈路增,刘晶华,等.超声造影及BRAF基因突变诊断甲状腺乳头状癌被膜外侵犯[J].中国医学影像技术,2020,36(1):50-54.
[28] Lee DH, Kim YK, Yu HW, et al. Computed tomography for detecting cervical lymph node metastasis in patients who have papillary thyroid microcarcinoma with tumor characteristics appropriate for active surveillance[J]. Thyroid,2019,29(11):1653-1659.
[29] Hirokawa M, Kudo T, Ota H, et al. Pathological characteristics of low-risk papillary thyroid microcarcinoma with progression during active surveillance[J]. Endocr J, 2016,63(9):805-810.
[30] Yoshida Y, Horiuchi K, Okamoto T. Patients' view on the management of papillary thyroid microcarcinoma: Active surveillance or surgery[J]. Thyroid,2020,30(5):681-687.
[31] Jeon MJ, Lee YM, Sung TY, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: A cross-sectional study[J]. Thyroid,2019,29(7):956-962.
[32] Kong SH, Ryu J, Kim MJ, et al. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro) [J]. Thyroid, 2019,29(8):1089-1096.